×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KALA – kala pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KALA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/4
08:14 am
kala
KALA BIO, Inc. (NASDAQ: KALA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Medium
Report
KALA BIO, Inc. (NASDAQ: KALA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
3/31
08:00 am
kala
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Medium
Report
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
2/26
08:00 am
kala
KALA BIO to Present at TD Cowen 45th Annual Health Care Conference
Low
Report
KALA BIO to Present at TD Cowen 45th Annual Health Care Conference
2/13
08:10 am
kala
KALA BIO, Inc. (NASDAQ: KALA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Medium
Report
KALA BIO, Inc. (NASDAQ: KALA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
2/12
08:00 am
kala
KALA BIO Announces Chief Executive Officer Transition
High
Report
KALA BIO Announces Chief Executive Officer Transition
Date
Time
Symbol
Company Name
Action
%Chg
3/31/2025
08:00 am
kala
kala pharmaceuticals, inc.
BEAT
Report
-4.5%
kala pharmaceuticals, inc.
11/12/2024
08:00 am
kala
kala pharmaceuticals, inc.
BEAT
Report
-4.1%
kala pharmaceuticals, inc.
8/6/2024
08:00 am
kala
kala pharmaceuticals, inc.
BEAT
Report
5.8%
kala pharmaceuticals, inc.
5/14/2024
04:05 pm
kala
kala pharmaceuticals, inc.
MISS
Report
-1.6%
kala pharmaceuticals, inc.
Date
Time
Symbol
Headline
Impact
4/11
04:19 pm
kala
Form 8-K KALA BIO, Inc. For: Apr 10
Medium
Report
Form 8-K KALA BIO, Inc. For: Apr 10
3/31
08:03 am
kala
Form 10-K KALA BIO, Inc. For: Dec 31
Medium
Report
Form 10-K KALA BIO, Inc. For: Dec 31
3/31
08:01 am
kala
Form 8-K KALA BIO, Inc. For: Mar 31
Medium
Report
Form 8-K KALA BIO, Inc. For: Mar 31
3/10
08:00 pm
kala
Form 4 KALA BIO, Inc. For: Mar 07 Filed by: Bazemore Todd
Medium
Report
Form 4 KALA BIO, Inc. For: Mar 07 Filed by: Bazemore Todd
2/14
09:04 pm
kala
Form SCHEDULE 13G/A KALA BIO, Inc. Filed by: ADAR1 Capital Management, LLC
High
Report
Form SCHEDULE 13G/A KALA BIO, Inc. Filed by: ADAR1 Capital Management, LLC
2/14
03:02 pm
kala
Form SCHEDULE 13G KALA BIO, Inc. Filed by: Cormorant Asset Management, LP
Low
Report
Form SCHEDULE 13G KALA BIO, Inc. Filed by: Cormorant Asset Management, LP
2/12
08:06 am
kala
Form 8-K KALA BIO, Inc. For: Feb 11
High
Report
Form 8-K KALA BIO, Inc. For: Feb 11
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/3
Form 4 Kala Pharmaceuticals, For: Jan 02 Filed by: Brazzell Romulus K
26.4%
3/7 Kala Pharmaceuticals Inc (NASDAQ: KALA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $7.00 price target on the stock. 26.3%
8/8 Kala Pharmaceuticals Inc (NASDAQ: KALA) was given a new $9.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a "buy" rating on the stock. 24.0%
8/7 Kala Pharmaceuticals Inc (NASDAQ: KALA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock, down previously from $15.00. 17.2%
11/7 Form 10-Q Kala Pharmaceuticals, For: Sep 30 10.8%
4/17 Kala Pharmaceuticals Inc (NASDAQ: KALA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $10.00 price target on the stock. 8.0%
4/1 Form 4 Kala Pharmaceuticals, For: Mar 30 Filed by: Chen Hongming 7.7%
10/21 Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 6.8%
4/13 Form 4 Kala Pharmaceuticals, For: Apr 09 Filed by: Brazzell Romulus K 6.8%
6/3 Form 4 Kala Pharmaceuticals, For: May 30 Filed by: Rosen Howard B 6.2%
3/7 Kala Pharmaceuticals Inc (NASDAQ: KALA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $7.00 price target on the stock. 26.3%
8/8 Kala Pharmaceuticals Inc (NASDAQ: KALA) was given a new $9.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a "buy" rating on the stock. 24.0%
8/7 Kala Pharmaceuticals Inc (NASDAQ: KALA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock, down previously from $15.00. 17.2%
11/7 Form 10-Q Kala Pharmaceuticals, For: Sep 30 10.8%
4/17 Kala Pharmaceuticals Inc (NASDAQ: KALA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $10.00 price target on the stock. 8.0%
4/1 Form 4 Kala Pharmaceuticals, For: Mar 30 Filed by: Chen Hongming 7.7%
10/21 Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 6.8%
4/13 Form 4 Kala Pharmaceuticals, For: Apr 09 Filed by: Brazzell Romulus K 6.8%
6/3 Form 4 Kala Pharmaceuticals, For: May 30 Filed by: Rosen Howard B 6.2%
TOP News Decliners
3/11
Form 8-K Kala Pharmaceuticals, For: Mar 10
-16.0%
8/6 Form 8-K Kala Pharmaceuticals, For: Aug 06 -15.9%
8/3 Kala Pharmaceuticals Inc (NASDAQ: KALA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.75 price target on the stock. -15.1%
12/17 Kala Pharmaceuticals Inc (NASDAQ: KALA) was downgraded by analysts at Bank of America Corp from a "buy" rating to a "neutral" rating. They now have a $6.00 price target on the stock, down previously from $9.00. -13.2%
3/12 Form 424B5 Kala Pharmaceuticals, -8.8%
4/30 Kala Pharmaceuticals to Report First Quarter 2020 Financial Results and Host Conference Call -8.7%
1/21 Kala Pharmaceuticals Inc (NASDAQ: KALA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock. -8.4%
4/28 Kala Pharmaceuticals Inc (NASDAQ: KALA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $11.00 price target on the stock. -7.5%
3/10 Kala Pharmaceuticals Inc (NASDAQ: KALA) had its price target raised by analysts at Wedbush from $51.00 to $52.00. They now have an "outperform" rating on the stock. -7.1%
5/9 Form 10-Q Kala Pharmaceuticals, For: Mar 31 -6.5%
8/6 Form 8-K Kala Pharmaceuticals, For: Aug 06 -15.9%
8/3 Kala Pharmaceuticals Inc (NASDAQ: KALA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.75 price target on the stock. -15.1%
12/17 Kala Pharmaceuticals Inc (NASDAQ: KALA) was downgraded by analysts at Bank of America Corp from a "buy" rating to a "neutral" rating. They now have a $6.00 price target on the stock, down previously from $9.00. -13.2%
3/12 Form 424B5 Kala Pharmaceuticals, -8.8%
4/30 Kala Pharmaceuticals to Report First Quarter 2020 Financial Results and Host Conference Call -8.7%
1/21 Kala Pharmaceuticals Inc (NASDAQ: KALA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock. -8.4%
4/28 Kala Pharmaceuticals Inc (NASDAQ: KALA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $11.00 price target on the stock. -7.5%
3/10 Kala Pharmaceuticals Inc (NASDAQ: KALA) had its price target raised by analysts at Wedbush from $51.00 to $52.00. They now have an "outperform" rating on the stock. -7.1%
5/9 Form 10-Q Kala Pharmaceuticals, For: Mar 31 -6.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: